3D MEDICINES (01244.HK): Envafolimab Moves to Regular Approval

On 18 November 2026, 3D MEDICINES (01244.HK) said NMPA approved on 17 November the switch of Envafolimab to regular approval, notice No. 2026B08210, in China.

NewTimeSpace News: On 18 November 2026, 3D Medicines Inc. (stock code: 01244) announced that the NMPA approved on 17 November 2026 the supplemental application for 恩維達® (Envafolimab Injection) to transition from conditional approval to regular approval as a domestically produced drug, under notice of approval No. 2026B08210.

Envafolimab is a recombinant humanised single-domain antibody against programmed death ligand 1 fused with an Fc region. It was independently developed by Alphamab Oncology (stock code: 09966) and has been co-developed with the Company since 2016. In March 2020, Jiangsu Alphamab, 3D Medicines and Jiangsu Simcere entered into a cooperation agreement granting Jiangsu Simcere the exclusive marketing rights for Envafolimab in oncology indications in mainland China.

In January 2024, the Company and Alphamab entered into a licence agreement granting Glenmark exclusive rights and sublicences to develop and commercialise Envafolimab for oncology indications in India, Asia-Pacific excluding Singapore, Thailand and Malaysia, the Middle East and Africa, Russia, CIS countries and Latin America. Envafolimab, the world's first subcutaneous PD-L1 inhibitor, was approved in China in November 2021 for adults with unresectable or metastatic MSI-H or dMMR advanced solid tumours.

Pursuant to Rule 18A.05, the Company cautioned that it may not be able to successfully develop and/or market Envafolimab for indications other than the approved previously treated MSI-H/dMMR advanced solid tumours.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.